E. Claire Dees - Concepedia

Author

E. Claire Dees

UNC Lineberger Comprehensive Cancer Center

Also Known As

Antonia, Scott, Cohen, Roger B., Collichio, Frances A., Dees, E. Claire, E Claire Dees, E C Dees, E Claire Dees, E DEES, E. C. Dees, E. Claire Dees

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Sarah Cannon Tennessee Oncology Fox Chase Cancer Center

About

E. Claire Dees is an author at UNC Lineberger Comprehensive Cancer Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	829
2	Health Sciences	3	3	96
3	Cell Biology	3	3	59
4	Engineering	1	1	55
5	Nursing	1	1	41

E. Claire Dees

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies Neil L. Spector, Wenle Xia, Howard A. Burris, Journal of Clinical Oncology	2005	363
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart, The Lancet Oncology Investigational AuroraMedicinePharmacologyPathologyBreast Cancer	2015	248
The interaction of post‐traumatic growth and post‐traumatic stress symptoms in predicting depressive symptoms and quality of life Edward Forrest Morrill, Noel T. Brewer, Suzanne C. O’Neill, Psycho-Oncology	2008	246
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Journal of Clinical Oncology	2009	207
Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors Jeffrey R. Infante, E. Claire Dees, Anthony J. Olszanski, Journal of Clinical Oncology	2014	205
Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study AH Partridge, K. O. Adloff, Emily Blood, JNCI Journal of the National Cancer Institute	2008	172
Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer Rita Nanda, Laura Q.M. Chow, E. Claire Dees, Cancer Research Breast OncologyImmunologyImmunoeditingPathologyImmunotherapeutics	2015	114
Axillary lymph node count is lower after neoadjuvant chemotherapy Heather B. Neuman, Lisa A. Carey, David W. Ollila, The American Journal of Surgery Surgical OncologyMedicinePathologyBreast CancerBreast Surgery	2006	69
A Phase I and Pharmacokinetic Study of Short Infusions of UCN-01 in Patients with Refractory Solid Tumors E. Claire Dees, Sharyn D. Baker, Séamus O’Reilly, Clinical Cancer Research Surgical OncologyPharmacokinetic StudyPharmacotherapyRefractory Solid TumorsMetronomic Chemotherapy	2005	68
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003) Nancy U. Lin, Hao Guo, Jeffrey T. Yap, Journal of Clinical Oncology	2015	65

Page 1